Eli Lilly and Company
8 rounds tracked since 18 March 2026.
- Rounds
- 8
- Led
- 0
- Capital in these rounds
- $818M
Sectors
Countries
Rounds
- ThatchProvides employers with health budgets and individual insurance benefit infrastructure $108MSeries C · 15 Sept
- Superluminal MedicinesDevelops small-molecule medicines targeting GPCRs and metabolic diseases $60MSeries B · 3 Sept
- InduProDevelops bispecific and multispecific therapeutics for oncology using a platform that brings cell surface proteins closer together. $77MSeries B · 13 Aug
- AmplificaDevelops injectable therapies that stimulate hair follicle regeneration and growth. $26MSeries B · 12 Aug
- Ratio TherapeuticsClinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment $70MSeries C · 31 Jul
- AdvanCellDevelops targeted alpha therapies for cancer and expands clinical and commercial manufacturing capacity. $315MSeries D · 15 Jul
- Flare TherapeuticsDiscovers and develops precision medicines by targeting transcription factors, focusing on prostate cancer. $85MSeries C · 30 Jun
- Crossbow TherapeuticsDevelops T-cell engager antibody therapies to treat a broad range of cancers. $77MSeries B · 18 Mar
Often invests with
The Daily Raise
The day's rounds in your inbox each morning.
Subscribe to The Daily Raise